Sirona Dental Systems Inc. (NASDAQ:SIRO) filed Annual Report for the period ended 2009-09-30.
Sirona Dental Systems Inc. is a company dedicated to creating and producing the finest dental equipment available. Its leading global position rests on our commitment to technological innovation, manufacturing excellence and international sales expertise. It is combined with a highly skilled workforce, enables us to deliver and distribute products and services that give our customers the advantages necessary for today's and tomorrow's demands. All Sirona products represent the cutting-edge of modern dental treatment, research and development. Sirona Dental Systems Inc. has a market cap of $1.71 billion; its shares were traded at around $31.16 with a P/E ratio of 18.2 and P/S ratio of 2.3. Sirona Dental Systems Inc. had an annual average earning growth of 58.8% over the past 5 years.
Highlight of Business Operations:Sironas revenue for the fiscal year ended September 30, 2009 was $713.3 million. Sirona sells its products globally, with the U.S. market contributing 31% of revenue, or $221.2 million, the German market contributing 21% of revenue, or $147.3 million, and the rest of the world contributing 48% of revenue, or $344.8 million.
On April 27, 1998, Sirona and Patterson Companies entered into an exclusive distribution agreement (the Distribution Agreement) pursuant to which Patterson was appointed as the exclusive distributor of Sironas CEREC CAD/CAM products within the United States and Canada. Under the terms of the Distribution Agreement, Pattersons exclusivity was to terminate on September 30, 2007. On June 30, 2005, Sirona and Patterson entered into an amendment of the Distribution Agreement which extended Pattersons exclusivity from October 1, 2007 through September 30, 2017. As consideration for the extension of its exclusivity, Patterson agreed to make a one-time payment to Sirona in the amount of $100 million (the Exclusivity Fee). In July 2005, Patterson paid the Exclusivity Fee, in its entirety, to Sirona. The full amount of the Exclusivity Fee was recorded as deferred income and is being recognized on a straight-line basis commencing on October 1, 2007. In the event of termination of the Distribution Agreement (a) due to force majeure, (b) by Patterson due to Sironas insolvency, or (c) by Sirona as a result of a failure by Patterson to meet its performance obligations, Sirona would be required to refund to Patterson a portion of the Exclusivity Fee as liquidated damages. The amount of the Exclusivity Fee required to be refunded declines by $15 million per year in each of fiscal 2008 through 2012 and by $5 million per year thereafter. In the event of termination by Patterson due to a breach by Sirona of its exclusivity obligations, the unearned portion of the Exclusivity Fee (as determined on a straight-line basis beginning in fiscal 2008) must be refunded to Patterson as liquidated damages. The extension did not modify or alter the underlying provisions of the companies agreement through 2007, including the performance criteria necessary to maintain the exclusivity. The performance criteria are benchmark thresholds which afford Sirona the opportunity to abandon the exclusivity or to terminate the agreement with Patterson, but do not create minimum purchase obligations under a take-or-pay arrangement.
Sirona commits significant resources to research and development, with a particular focus on developing products that offer new diagnostic and treatment options, while increasing user comfort and streamlining process efficiency. Sirona spent approximately $41 million, $49 million and $47 million on research and development activities in the fiscal years ended September 30, 2009, 2008 and 2007, respectively, which represented approximately 6% of Sironas total revenue in each year. Sirona employs 194 professionals in its global research and development departments. Sirona also cooperates in its research efforts with partners in research facilities and dental practices around the world.
Read the The complete Report